SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing a sharp sell-off driven by a confluence of negative sentiment, including a federal jury finding that Elon Musk defrauded Twitter shareholders and concerns regarding broader macroeconomic instability. The community is deeply divided, with bears pointing to falling delivery numbers and operational scrutiny as evidence of a structural decline, while loyal bulls continue to highlight upcoming projects like TeraFab and the potential for a rebound as reasons to maintain their positions.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as investors debate the long-term potential of the project, with many in the community expressing unwavering patience for a future breakout despite current price volatility. Supporters are actively highlighting the project's utility and health-focused mechanics, often drawing comparisons to historical market recoveries to justify their continued accumulation.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility as investors debate the impact of the Kodiak Building Partners acquisition alongside ongoing concerns regarding share dilution and macro headwinds in the construction sector. While some community members remain bullish on Brad Jacobs' long-term consolidation strategy and anticipated acquisition pipeline, others are expressing frustration over the recent downward price pressure and uncertainty surrounding the integration timeline.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as investors focus on its integration into the AI-native economy, with community discussion highlighting its role in chain abstraction, privacy-focused protocols, and recent infrastructure developments. Many are closely watching the balance between retail accumulation and institutional activity while expressing optimism about its long-term utility in the decentralized AI landscape.

LayerX is a web3 infrastructure and innovation ecosystem focused on helping builders go from idea to real, sustainable products. The platform connects hackathons, developer tools, incubation programs, and community-driven ecosystems under a single framework. LayerX supports both technical and non-technical participants by providing access to mentorship, partnerships, hackathons, onchain tasks, and more.  Its products enable teams to prototype, validate, and scale projects while aligning incentives between builders, communities, and partners. The LX token acts as the shared economic layer across the ecosystem, supporting participation, staking, governance, and access to ecosystem features.

LayerX

LayerX, formerly known as Bepro, is drawing significant community interest as investors discuss its low market capitalization, potential for long-term growth, and recent developments within its ecosystem. Supporters are actively sharing bullish perspectives on the project's utility and future potential while tracking technical indicators and looking for signs of broader adoption.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is currently capturing significant market interest as it benefits from surging demand for AI-driven chip fabrication equipment, with community members actively monitoring its strong relative strength against industry peers. Investors are closely tracking upcoming earnings while debating the stock's valuation and potential upside against the backdrop of broader semiconductor sector consolidation.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone shares are under pressure as investors react to mixed signals regarding private credit exposure and shifting regulatory landscapes, despite the firm reporting a significant earnings beat and record assets under management. Market participants are actively debating whether the recent dip represents a buying opportunity in a high-growth financial leader or a warning sign of broader systemic risks within the alternative asset sector.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang is seeing intense activity fueled by a major insider buy following a recent data breach, alongside excitement regarding the company's new AI factory partnership with NVIDIA. The community is actively debating the stock's long-term growth potential and recovery prospects, with many traders closely watching technical support levels as the stock aims to reclaim higher price targets.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as community discussions center on the Supreme Court's potential involvement in its patent infringement case against Hikma, following the Solicitor General's filing. Investors are also closely monitoring the upcoming EMT2 trial results and potential M&A activity as the company continues its restructuring and cost-cutting initiatives.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors capitalize on its recent NYSE listing, which provides rare public market access to high-profile private AI and tech companies like Anthropic, OpenAI, and SpaceX. While the community is actively debating the significant premium over the fund's net asset value and the impact of a six-month lockup on available float, many are focused on the stock's high volatility and potential for momentum-driven price swings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company submitted an updated manuscript detailing a new two-step method to remove nearly all non-cancer DNA.</li><li>Early results showed no false positives and all cancers detected in the first group, along with strong validation in a second blinded cohort.</li><li>VolitionRx published a research paper in December 2025, that highlighted its Capture-Seq method for cancer detection.</li></ul>Shares of VolitionRx (VNRX) gave up a part of its pre-market gains to trade 30% higher on Wednesday after the diagnostics company unveiled what it called a potential breakthrough in cancer detection. The company said it was successful in isolating more than 99% pure circulating tumor-derived DNA (ctDNA) from blood samples of cancer patients.<a href="https://stocktwits.com/symbol/VNRX">VNRX stock</a> breached its 100-day moving average (100-DMA) for the first time since Oct. 8, 2025.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/chart/teA7VKVN/?symbol=AMEX%3AVNRX"><img src="https://news.stocktwits-cdn.com/VNRX_jpg_e886d96646.webp" alt="VNRX.jpg"></a>Source: TradingViewThe company submitted an updated manuscript detailing a new two-step method that combines physical sample enrichment with advanced bioinformatics to remove nearly all non-cancer DNA. This addresses a key challenge in liquid biopsy, where most circulating DNA typically comes from healthy cells.“Our continuing work on CTCF-bound DNA has revealed what we believe to be an unprecedented new discovery; that there is almost no CTCF-bound DNA in healthy plasma and almost all CTCF-bound DNA in the blood of a cancer patient is derived from cancer cells – i.e. it is virtually pure circulating tumor-derived DNA,” said Jake Micallef, Chief Scientific Officer of Volition.“Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long term goal of liquid biopsy. I believe this is a world-first and could, in my opinion, represent the biggest scientific breakthrough in cancer testing and monitoring in recent years,” Micallef added.The early results are encouraging, with no false positives and all cancers detected in the first group, along with strong validation in a second blinded cohort, VolitionRx said. The company is now working on further testing in early-stage cancers.<h2 class="st-heading-2">VolitionRx’s Capture-Seq Method for Cancer Detection</h2>VolitionRx published a research paper in December 2025, that highlighted its Capture-Seq method and novel biomarkers for cancer detection. The technology enables accurate and potentially low-cost testing across multiple cancers.&nbsp;It works by enriching ultrashort DNA fragments in blood, achieving a 180-fold increase in detection sensitivity. This approach focuses on DNA within chromosome fragments, unlike traditional methods that analyze extracted DNA.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits completely flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.Despite shedding gains, retail chatter remained primarily bullish, with one user asking for patience.<stembedurl>https://stocktwits.com/SuellenD/message/647851536</stembedurl>Another user said buy the dip.<stembedurl>https://stocktwits.com/SuellenD/message/647840635</stembedurl>Year-to-date, the stock has shed around 8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Why Is VNRX Stock Soaring Over 30% Today?

The company said it can isolate pure tumor DNA from blood, which potentially solves a key bottleneck in liquid biopsy.

Equity

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating...

Volition Announces First Ever Automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems

Volition Announces First Ever Automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems Volition Announces First Ever Automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems PR Newswire HENDERSON...

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution PR Newswire HENDERSON, Nev., Feb. 25, 2026 HENDERSON, Nev...

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards PR Newswire...

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q Cancer Assays

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q Cancer Assays VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q Cancer Assays...

Volition Announces Data to Support Use of Nu.Q NETs in New Indication

Volition Announces Data to Support Use of Nu.Q NETs in New Indication Volition Announces Data to Support Use of Nu.Q NETs in New Indication PR Newswire HENDERSON, Nev., Jan. 27, 2026 Nu.Q Biomarker...

Volition Continues to Extend Access to Nu.Q Vet Cancer Test

Volition Continues to Extend Access to Nu.Q Vet Cancer Test Volition Continues to Extend Access to Nu.Q Vet Cancer Test PR Newswire HENDERSON, Nev., Jan. 20, 2026 HENDERSON, Nev., Jan. 20, 2026...

Volition Sponsors Symposium at Veterinary Meeting and Expo

Volition Sponsors Symposium at Veterinary Meeting and Expo Volition Sponsors Symposium at Veterinary Meeting and Expo PR Newswire HENDERSON, Nev., Jan. 16, 2026 HENDERSON, Nev., Jan. 16, 2026...

VolitionRx Secures $2.0 Million in Funding

VolitionRx Secures $2.0 Million in Funding VolitionRx Secures $2.0 Million in Funding PR Newswire HENDERSON, Nev., Jan. 8, 2026 HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE...

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.04	--	--	N/A
Q3 '25	-$0.04	-$0.05	-13.64%	MISSED
Q2 '25	-$0.06	-$0.06	-7.14%	MISSED
Q1 '25	-$0.04	-$0.06	-38.89%	MISSED
Q4 '24	-$0.05	-$0.06	-9.09%	MISSED

VNRX
VolitionRX Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest VNRX News

VNRXVolitionRX Ltd